demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
Kinase inhibitors
imatinib Aman

4 studies excluded by filtering options 0

5271 Covid-19 HUF, 2021 110risk of bias not avaialble
5847 CALAVI, 2020 110risk of bias not avaialble
6039 CALAVI US, 2020 110risk of bias not avaialble
6323 Roschewski, 2020 2990excludednot a RCTrisk of bias not avaialble